The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

▎药明康德内容团队编辑辉瑞公司（Pfizer）日前宣布，美国FDA已加速批准BRAF抑制剂Braftovi（encorafenib）与Erbitux（cetuximab），及mFOLFOX6治疗方案（包括氟尿嘧啶、亚叶酸钙和奥沙利铂）联用，用于治疗检 ...

Old Alabama Barker Rushed to ER on Christmas Eve Following Nicotine Withdrawal appeared first on Where Is The Buzz | Breaking ...